{"id":24,"date":"2020-02-26T14:45:50","date_gmt":"2020-02-26T05:45:50","guid":{"rendered":"https:\/\/www.med.osaka-u.ac.jp\/pub\/hp-drug\/pharm\/cms\/?page_id=24"},"modified":"2026-04-22T11:01:05","modified_gmt":"2026-04-22T02:01:05","slug":"researchachievement","status":"publish","type":"page","link":"https:\/\/www.med.osaka-u.ac.jp\/pub\/hp-drug\/pharm\/researchachievement\/","title":{"rendered":"\u53d7\u8cde\u30fb\u8ad6\u6587\u767a\u8868"},"content":{"rendered":"
\n
\n
\n
\n
2026\u5e74<\/span><\/div>\n
\n

\u53d7\u8cde<\/h2>\n
    \n
  1. \u6e05\u672c \u7434\u6dd1<\/span>\u3000\u65e5\u672c\u85ac\u5b66\u4f1a\u7b2c146\u5e74\u4f1a
    \n\u5b66\u751f\u512a\u79c0\u767a\u8868\u8cde\uff08\u30dd\u30b9\u30bf\u30fc\u767a\u8868\u306e\u90e8\uff09<\/span><\/a>
    \n\u5b9f\u81e8\u5e8a\u30c7\u30fc\u30bf\u3092\u7528\u3044\u305f\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u8a98\u767a\u6027\u814e\u969c\u5bb3\u306e\u6a5f\u68b0\u5b66\u7fd2\u30d9\u30fc\u30b9\u4e88\u6e2c\u30e2\u30c7\u30eb\u306e\u69cb\u7bc9<\/span><\/li>\n
  2. \u9577\u8c37 \u5f69\u82b1<\/span>\u3000\u5927\u962a\u5927\u5b66\u85ac\u5b66\u90e8\u3000\u4ee4\u548c7\u5e74\u5ea6\u9577\u671f\u8ab2\u984c\u7814\u7a76\u4e2d\u9593\u767a\u8868\u4f1a<\/span>
    \n\u512a\u79c0\u30dd\u30b9\u30bf\u30fc\u8cde<\/span><\/a>
    \n\u30de\u30eb\u30c1\u30c7\u30fc\u30bf\u89e3\u6790\u306b\u3088\u308b\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u8a98\u767a\u6027\u814e\u969c\u5bb3\u306b\u5bfe\u3059\u308b\u65b0\u898f\u4e88\u9632\u85ac\u306e\u63a2\u7d22<\/span><\/li>\n
  3. <\/li>\n
  4. <\/li>\n
  5. <\/li>\n<\/ol>\n<\/div>\n

    2025\u5e74<\/span><\/p>\n<\/div>\n

    \n

    \u53d7\u8cde<\/h2>\n
      \n
    1. \u5965\u7530 \u771f\u5f18<\/span>\u30002025\u5e74\u5ea6\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u8cde<\/span><\/a>
      \n\u85ac\u7269\u30c8\u30e9\u30f3\u30b9\u30dd\u30fc\u30bf\u304c\u95a2\u308f\u308b\u81e8\u5e8a\u85ac\u7269\u76f8\u4e92\u4f5c\u7528\u306b\u57fa\u3065\u304f\u533b\u7642\u85ac\u5b66\u7814\u7a76<\/span><\/li>\n
    2. \u65b0\u8c37 \u62d3\u4e5f<\/span>\u3000\u533b\u7642\u306e\u8cea\u30fb\u5b89\u5168\u5b66\u4f1a\u3000\u7b2c11\u56de\u4e0a\u539f\u9cf4\u592b\u8a18\u5ff5\u7814\u7a76\u5968\u52b1\u8cde<\/span><\/span>
      \n\u56fd\u969b\u5b66\u4f1a\u767a\u8868\u5968\u52b1\u8cde<\/span><\/a><\/li>\n
    3. \u690d\u91ce \u611b\u7f8e<\/span>\u3000\u5927\u962a\u5927\u5b66\u85ac\u5b66\u90e8\u3000\u4ee4\u548c6\u5e74\u5ea6\u9577\u671f\u8ab2\u984c\u7814\u7a76\u4e2d\u9593\u767a\u8868\u4f1a<\/span>
      \n\u512a\u79c0\u30dd\u30b9\u30bf\u30fc\u8cde<\/span><\/a>
      \n\u30aa\u30ad\u30b5\u30ea\u30d7\u30e9\u30c1\u30f3\u8a98\u767a\u6027\u672b\u68a2\u795e\u7d4c\u969c\u5bb3\u306b\u5bfe\u3059\u308b\u65b0\u898f\u4e88\u9632\u6cd5\u306e\u958b\u767a<\/span><\/li>\n
    4. \u690d\u91ce \u611b\u7f8e\u3000\u65e5\u672c\u85ac\u5b66\u4f1a\u7b2c145\u5e74\u4f1a
      \n\u5b66\u751f\u512a\u79c0\u767a\u8868\u8cde\uff08\u53e3\u982d\u767a\u8868\u306e\u90e8\uff09<\/span><\/a>
      \n\u30a8\u30bd\u30e1\u30d7\u30e9\u30be\u30fc\u30eb\u306f\u6709\u6a5f\u30ab\u30c1\u30aa\u30f3\u30c8\u30e9\u30f3\u30b9\u30dd\u30fc\u30bf2<\/span>\u306e\u963b\u5bb3\u306b\u3088\u308a\u30aa\u30ad\u30b5\u30ea\u30d7\u30e9\u30c1\u30f3\u8a98\u767a\u6027\u672b\u68a2\u795e\u7d4c\u969c\u5bb3\u3092\u4e88\u9632\u3059\u308b<\/span><\/li>\n<\/ol>\n

      \u8ad6\u6587\u767a\u8868<\/h2>\n
        \n
      1. Tang N, Maeda S, Okuda M. <\/span>
        \nPopulation pharmacokinetic\/pharmacodynamic model of the impact of cumulative tacrolimus exposure on kidney function after liver transplant<\/span><\/span>.
        \nTher Drug Monit. <\/span><\/span>(2025) in press DOI:         10.1097\/FTD.0000000000001418.<\/span><\/a><\/span><\/li>\n
      2. Ueno M, Kobayashi A, Ikemurak K, Wakai E, Yamane F, Okuda M. <\/span>
        \nEsomeprazole prevents oxaliplatin-induced peripheral neuropathy through inhibiting organic cation transporter 2 in mice<\/span><\/span>.
        \nEur J Pharm Sci. 214: 107309 <\/span><\/span>(2025) DOI:         10.1016\/j.ejps.2025.107309<\/a>.<\/a><\/span><\/li>\n
      3. Ikemura K, Kobayashi S, Wang D, Okuda M. <\/span>
        \nContribution of organic anion transporter 3 in delayed elimination of methotrexate by concomitant administration of febuxostat<\/span><\/span>.
        \nBiopharm Drug Dispos. 46(4): 165-171 <\/span><\/span>(2025) DOI:         10.1002\/bdd.70014.<\/a><\/span><\/li>\n
      4. Takemura M, Ikemura K, Okuda M. <\/span>
        \nFactors and preventive strategies for perioperative euglycemic diabetic ketoacidosis in patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors: a retrospective study.
        \nJ Pharm Health Care Sci. 11:79 (2025) DOI:         10.1186\/s40780-025-00487-6<\/span>.<\/a><\/span><\/li>\n
      5. Kondo M, Yamane F, Kawashima K, Ikemura K, Okuda M. <\/span>
        \nProtective effect of palonosetron against cisplatin-induced cytotoxicity via<\/em> decreased phosphorylation of p38.
        \nBio Pharm Bull. 48(7): 1142-1149 (2025) DOI:         10.1248\/bpb.b25-00193.<\/a><\/span><\/li>\n
      6. Kobayashi A, Ikemura K, Ueno M, Wakai E, Yamane F, Okuda M. <\/span>
        \nLansoprazole identified as a prophylactic agent for oxaliplatin-induced peripheral neuropathy using integrated in silico<\/em>, in vitro<\/em>, and in vivo<\/em> analyses.<\/span><\/span>
        \nBiomed Pharmacother. 189: 118272 (2025) DOI:         10.1016\/j.biopha.2025.118272.<\/a><\/span><\/li>\n
      7. Bai L, Sakimura S, Niwa Y, Mizuguchi H, Maeda S, Ikemura K, Okuda M, Kondoh M.<\/span>
        \nAn vitro safety evaluation model for assessing the effects of a chemical drug on the human intestinal barrier integrity using genetically modified Caco-2 cells expressing drug-metabolizing enzymes<\/span>
        \nToxicol Lett. 410:113-120 (2025) DOI:         <\/a><\/span><\/span>10.1016\/j.toxlet.2025.06.003<\/a><\/span><\/li>\n
      8. Yamane F, Ikemura K, Kondo M, Ueno M, Okuda M. <\/span>
        \nIdentification of dequalinium as a potent inhibitor of human organic cation transporter 2 by machine learning based QSAR model<\/span>.<\/span>
        \nSci Rep. 15:2581 (2025) DOI:         10.1038\/s41598-024-79377-0.<\/span><\/a><\/span><\/li>\n
      9. Takemura M, Ikemura K, Okuda M. <\/span>
        \nEffect of hydration with bicarbonate ringer\u2019s solution on cisplatin-induced acute kidney injury in patients with esophageal cancer: A retrospective cohort study<\/span>.<\/span>
        \nOncology. 103(1): 22-29 (2025) DOI:         10.1159\/000540637.<\/a><\/span><\/li>\n
      10. <\/li>\n<\/ol>\n

        \u7dcf\u8aac<\/h2>\n
          \n
        1. \u6c60\u6751 \u5065\u6cbb\u00a0<\/span>
          \n\u6709\u6a5f\u30ab\u30c1\u30aa\u30f3\u30c8\u30e9\u30f3\u30b9\u30dd\u30fc\u30bf2\u3092\u6a19\u7684\u3068\u3057\u305f\u767d\u91d1\u7cfb\u6297\u304c\u3093\u85ac\u306e\u526f\u4f5c\u7528\u514b\u670d\u3092\u76ee\u6307\u3057\u305f\u57fa\u790e\u30fb\u81e8\u5e8a\u878d\u5408\u7814\u7a76<\/span>
          \n\u819c\u300150(4): 156-161 (2025)<\/span><\/li>\n
        2. <\/a><\/span><\/li>\n<\/ol>\n<\/div>\n
          2024\u5e74<\/span><\/div>\n
          \n
            \n
          1. <\/li>\n<\/ol>\n

            \u53d7\u8cde<\/h2>\n
              \n
            1. \u5965\u7530 \u771f\u5f18\u30002024\u5e74\u5ea6\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a \u529f\u7e3e\u8cde<\/span><\/a><\/li>\n
            2. \u65b0\u8c37 \u62d3\u4e5f\u3000\u533b\u7642\u306e\u8cea\u30fb\u5b89\u5168\u5b66\u4f1a \u7b2c10\u56de\u4e0a\u539f\u9cf4\u592b\u8a18\u5ff5\u7814\u7a76\u5968\u52b1\u8cde\u3000\u6700\u512a\u79c0\u8cde<\/span><\/a><\/li>\n
            3. \u5ddd\u5cf6 \u5eb7\u592a\u6717<\/span>\u3000\u5927\u962a\u5927\u5b66\u85ac\u5b66\u90e8\u3000\u4ee4\u548c5\u5e74\u5ea6\u9577\u671f\u8ab2\u984c\u7814\u7a76\u4e2d\u9593\u767a\u8868\u4f1a<\/span>
              \n\u512a\u79c0\u30dd\u30b9\u30bf\u30fc\u8cde<\/span><\/a>
              \n\u30c0\u30b5\u30c1\u30cb\u30d6\u306e\u6297\u816b\u760d\u52b9\u679c\u5897\u5f37\u3092\u72d9\u3063\u305f\u65b0\u898f\u6cbb\u7642\u6226\u7565\u306e\u958b\u767a<\/span><\/li>\n<\/ol>\n

              \u8ad6\u6587\u767a\u8868<\/h2>\n
                \n
              1. Kawashima K, Ikemura K, Takemura M, Toyozumi Y, Okuda M. <\/span>
                \nFebuxostat enhances the efficacy of dasatinib by inhibiting ATP-binding cassette subfamily G member 2 (ABCG2) in chronic myeloid leukemia cells<\/span><\/span>.<\/span>
                \nBiomed Pharmacother. 181: 117709 (2024) DOI:                 10.1016\/j.biopha.2024.117709.<\/span><\/span><\/a><\/span><\/li>\n
              2. Shintani T, Shun YT, Toyozumi Y, Ikemura K, Shiroyama T, Nagatomo I, Jingushi K, Takeda Y, Kumanogoh A, Okuda M. <\/span>
                \nMicroRNA-130a-3p regulates osimertinib resistance by targeting runt-related transcription factor 3 in lung adenocarcinoma.<\/span>
                \nSci Rep. 14(1):24429 (2024) DOI:                 10.1038\/s41598-024-76196-1.<\/a><\/span><\/li>\n
              3. Wang D, Ikemura K, Hasegawa T, Yamane F, Okuda M. <\/span>
                \nContribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia.<\/span>
                \nBiomed Pharmacother. 175: 116801 (2024) DOI:                 10.1016\/j.biopha.2024.116801.<\/a><\/span><\/li>\n
              4. Hara S, Sakai D, Ikemura K, Shintani T, Yamamoto T, Satoh T, Okuda M. <\/span>
                \nComparative efficacy and safety of standard and biweekly trifluridine\/tipiracil regimen in patients with colorectal cancer.<\/span>
                \nAnticancer Res. 44: 1219-1226 (2024) DOI:                10.21873\/anticanres.16917.<\/a><\/span><\/li>\n
              5. Shimamoto Y, Fukushima K, Mizuno T, Ichikawa H, Kurosaki K, Maeda S, Okuda M.
                \nModel-informed vancomycin dosing optimization to address delayed renal maturation in infants and young children with critical congenital heart disease. <\/span>
                \nClin Pharmacol Ther. 115(2):239-247 (2024) DOI:                 10.1002\/cpt.3095.<\/a><\/span><\/li>\n
              6. Hata K, Nakamura K, Maeda S, Maeda M, Fujio Y, Hirobe S.
                \nInfusion-related reactions subsequent to avelumab, durvalumab, and atezolizumab administration: A retrospective observation study. <\/span>
                \nClin Pract. 14(2):377-387 (2024) DOI:                 10.3390\/clinpract14020029.<\/a><\/span><\/li>\n
              7. <\/li>\n<\/ol>\n<\/div>\n

                2023\u5e74<\/span><\/p>\n<\/div>\n

                \n

                \u53d7\u8cde<\/h2>\n
                  \n
                1. \u5510\u3000\u5be7\u4f73\uff08Ningjia Tang\uff09\u3000\u65e5\u672c\u85ac\u5b66\u4f1a\u7b2c143\u5e74\u4f1a
                  \n\u5b66\u751f\u512a\u79c0\u767a\u8868\u8cde\uff08\u30dd\u30b9\u30bf\u30fc\u767a\u8868\u306e\u90e8\uff09<\/span><\/a>
                  \nPopulation pharmacokinetics of tacrolimus in adult liver transplant patients in the first year<\/span><\/li>\n
                2. \u4e2d\u5ca1 \u771f\u60a0\u5b50<\/span>\u3000\u7b2c12\u56de\u65e5\u672c\u85ac\u5264\u5e2b\u30ec\u30b8\u30c7\u30f3\u30c8\u30d5\u30a9\u30fc\u30e9\u30e0<\/span>
                  \n\u512a\u79c0\u30dd\u30b9\u30bf\u30fc\u8cde<\/span><\/a>
                  \n\u6297\u83cc\u85ac\u306e\u5b9a\u6570\u914d\u7f6e\u5ec3\u6b62\u306b\u4f34\u3046\u7dca\u6025\u642c\u9001\u5bfe\u5fdc\u3068\u305d\u306e\u8a55\u4fa1<\/span><\/li>\n
                3. <\/li>\n<\/ol>\n

                  \u8ad6\u6587\u767a\u8868<\/h2>\n
                    \n
                  1. Kobayashi A, Ikemura K, Wakai E, Kondo M, Okuda M. <\/span>
                    \nProton pump inhibitors ameliorate oxaliplatin-induced peripheral neuropathy: retrospective analysis of two real-world clinical databases.<\/span>
                    \nAnticancer Res. 43(12): 5613-5620 (2023) DOI:                     10.21873\/anticanres.16764<\/span>.<\/a><\/span><\/li>\n
                  2. Kojima T, Kinoshita N, Kitamura H, Tanaka K, Tokunaga A, Nakagawa S, Abe T, Nakajima K. <\/span>
                    \nEffect of improvement measures in reducing interruptions in a Japanese hospital pharmacy using a synthetic approach based on resilience engineering and system thinking.<\/span>
                    \nBMC Health Serv Res. 23(1):331 (2023) DOI:                     10.1186\/s12913-023-09346-2<\/span>.<\/a><\/span><\/li>\n
                  3. Kato T, Enokiya T, Morikawa Y, Okuda M, Imai H.<\/span>
                    \nSequestration of antimicrobial agents in Xcoating and heparin-coated extracorporeal membrane oxygenation circuits: an in vitro study.\u00a0<\/span>
                    \nASAIO J.\u00a0 69(1):e23-e27 (2023) DOI:                     10.1097\/MAT.0000000000001842.<\/a><\/span><\/li>\n
                  4. \u65b0\u8c37 \u62d3\u4e5f, \u5317\u6751 \u6e29\u7f8e, \u517c\u5150 \u654f\u6d69, \u6b66\u7530 \u7406\u5b8f , \u9580\u8107 \u88d5\u5b50, \u5965\u7530 \u771f\u5f18 , \u4e2d\u6751 \u4eac\u592a , \u4e2d\u5cf6 \u548c\u6c5f<\/span>
                    \n\u56fd\u7acb\u5927\u5b66\u75c5\u9662\u306b\u304a\u3051\u308b\u514d\u75ab\u6291\u5236\u30fb\u5316\u5b66\u7642\u6cd5\u6642\u306e B \u578b\u809d\u708e\u518d\u6d3b\u6027\u5316\u4e88\u9632\u5bfe\u7b56\u306b\u95a2\u3059\u308b\u5b9f\u614b\u8abf\u67fb
                    \n\u533b\u7642\u306e\u8cea\u30fb\u5b89\u5168\u5b66\u4f1a\u8a8c\u300118(2): 148-157 (2023)\u00a0<\/span><\/li>\n
                  5. \u4e0a\u6797 \u91cc\u7d75, \u6c60\u6751 \u5065\u6cbb, \u82e5\u4e95 \u6075\u91cc, \u6749\u672c \u6d69\u5b50, \u5e73\u4e95 \u5229\u5178, \u52a0\u85e4 \u79c0\u96c4, \u5411\u539f \u91cc\u4f73, \u77f3\u5009 \u5065, \u4eca\u4e95 \u5bdb, \u5ca9\u672c \u5353\u4e5f<\/span>
                    \n\u96c6\u4e2d\u6cbb\u7642\u5ba4\u306e\u5c02\u4efb\u85ac\u5264\u5e2b\u306b\u3088\u308b\u6ce8\u5c04\u51e6\u65b9\u767a\u884c\u524d\u9451\u67fb\u304c\u85ac\u7269\u6cbb\u7642\u306e\u9069\u6b63\u5316\u306b\u53ca\u307c\u3059\u52b9\u679c
                    \n\u65e5\u672c\u81e8\u5e8a\u6551\u6025\u533b\u5b66\u4f1a\u96d1\u8a8c\u300126(1): 1-9 (2023) DOI:                     10.11240\/jsem.26.1.<\/a><\/span><\/li>\n
                  6. \u7530\u58a8 \u6075\u5b50,\u5927\u6751 \u671b\u7f8e, \u4e0a\u6751 \u656c\u5b50, \u539f \u4f38\u8f14, \u6c34\u6728 \u6e80\u4f50\u592e<\/span>
                    \n\u6297\u304c\u3093\u85ac\u306b\u3088\u308b\u66dd\u9732\u306e\u5b9f\u614b\u3068\u5bfe\u7b56\u306e\u691c\u8a0e : \u5916\u6765\u5316\u5b66\u7642\u6cd5\u95a2\u9023\u65bd\u8a2d\u306e\u74b0\u5883\u8abf\u67fb\u3088\u308a
                    \n\u5927\u962a\u5927\u5b66\u770b\u8b77\u5b66\u96d1\u8a8c\u300129(1): 51-56 (2023) DOI:                     10.18910\/90031.<\/a><\/span><\/li>\n
                  7. <\/li>\n
                  8. <\/li>\n<\/ol>\n

                    \u7dcf\u8aac<\/h2>\n
                      \n
                    1. \u5c71\u672c\u667a\u4e5f\u00a0<\/span>
                      \nEGUIDE\u30d7\u30ed\u30b8\u30a7\u30af\u30c8\u306e\u6311\u6226<\/span>
                      \n\u30fc\u7cbe\u795e\u79d1\u9818\u57df\u306e\u56fd\u5185\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u306e\u6559\u80b2\u3068\u666e\u53ca\u306e\u63a8\u9032\u30fc<\/span>
                      \n\u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u96d1\u8a8c\u300159(2): 130-134 (2023)<\/span><\/li>\n<\/ol>\n<\/div>\n
                      <\/div>\n
                      2022\u5e74<\/span><\/div>\n
                      \n

                      \u53d7\u8cde<\/h2>\n
                        \n
                      1. \u5c0f\u6797 \u6689\u82f1<\/span>\u3000\u7b2c43\u56de\u65e5\u672c\u81e8\u5e8a\u85ac\u7406\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a<\/span><\/span>
                        \n\u512a\u79c0\u6f14\u984c\u8cde<\/span><\/a>
                        \n\u30aa\u30ad\u30b5\u30ea\u30d7\u30e9\u30c1\u30f3\u8a98\u767a\u672b\u68a2\u795e\u7d4c\u969c\u5bb3\u306b\u5bfe\u3059\u308b\u30d7\u30ed\u30c8\u30f3\u30dd\u30f3\u30d7\u963b\u5bb3\u85ac\u306e\u4e88\u9632\u52b9\u679c\u306b\u95a2\u3059\u308b\u5f8c\u65b9\u8996\u7684\u7814\u7a76<\/span><\/li>\n
                      2. \u7af9\u6751 \u7f8e\u7a42\u3000\u7b2c32\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a<\/span>
                        \nYoung Investigator’s Award\uff08\u5b66\u751f\uff09<\/span><\/a>
                        \n\u4e73\u304c\u3093\u60a3\u8005\u306b\u304a\u3051\u308b\u30ab\u30da\u30b7\u30bf\u30d3\u30f3\u8a98\u767a\u6027\u624b\u8db3\u75c7\u5019\u7fa4\u306b\u5bfe\u3059\u308b\u30d7\u30ed\u30c8\u30f3\u30dd\u30f3\u30d7\u963b\u5bb3\u85ac\u306e\u4e88\u9632\u52b9\u679c<\/span><\/li>\n
                      3. \u7af9\u6751 \u7f8e\u7a42\u3000\u533b\u7642\u85ac\u5b66\u30d5\u30a9\u30fc\u30e9\u30e02022\/\u7b2c30\u56de\u30af\u30ea\u30cb\u30ab\u30eb\u30d5\u30a1\u30fc\u30de\u30b7\u30fc\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0<\/span>
                        \n\u512a\u79c0\u30dd\u30b9\u30bf\u30fc\u8cde<\/span><\/a>
                        \n\u6162\u6027\u9aa8\u9ac4\u6027\u767d\u8840\u75c5\u60a3\u8005\u306b\u304a\u3051\u308b\u30c0\u30b5\u30c1\u30cb\u30d6\u306e\u6cbb\u7642\u52b9\u679c\u306b\u53ca\u307c\u3059\u30d5\u30a7\u30d6\u30ad\u30bd\u30b9\u30bf\u30c3\u30c8\u4f75\u7528\u306e\u5f71\u97ff<\/span><\/li>\n
                      4. \u5b6b <\/span>\u4e8e\u5a77 (YuTing Shun) The 21st Asian Conference on Clinical Pharmacy (ACCP2022)<\/span><\/a>
                        \n Best Poster (Student)<\/span>
                        \nExtracellular vesicle-derived miRNAs regulate osimertinib resistance in non-small cell lung cancer cell<\/span><\/li>\n<\/ol>\n

                        \u8ad6\u6587\u767a\u8868<\/h2>\n
                          \n
                        1. Bai L, Tachibana K, Murata M, Inoue T, Mizuguchi H, Maeda S,\u00a0Ikemura K, Okuda M, Kusakabe T, Kondoh M.<\/span>
                          \nA doxycycline-inducible CYP3A4-Caco-2 cell line as a model for evaluating safety of aflatoxin B1 in the human intestine.<\/span>
                          \nToxicol Lett. 370(1):1-6 (2022) DOI:\u00a0                          <\/a>10.1016\/j.toxlet.2022.09.005.<\/a><\/span><\/span><\/li>\n
                        2. Takemura M, Ikemura K, Kondo M, Yamane F, Ueda M, Okuda M. <\/span>
                          \nConcomitant palonosetron ameliorates cisplatin-induced nephrotoxicity, nausea, and vomiting: a retrospective cohort study and pharmacovigilance analysis.<\/span>
                          \nJ Pharm Health Care Sci. 8(1):21 (2022) DOI:                           10.1186\/s40780-022-00252-z.<\/a><\/span><\/li>\n
                        3. Wakai E, Ikemura K, Mizuno T, Takeuchi K, Tamaru S, Okuda M, Nishimura Y. <\/span>
                          \nRepositioning of lansoprazole as a protective agent against cisplatin-induced ototoxicity.<\/span>
                          \nFront Pharmacol. 13: 896760 (2022) DOI:                           10.3389\/fphar.2022.896760.<\/a><\/span><\/li>\n
                        4. Takemura M, Ikemura K, Yoshinami T, Toyozumi Y, Shintani T, Ueda M, Shimazu K, Okuda M. <\/span>
                          \nProton pump inhibitors ameliorate capecitabine-induced hand-foot syndrome in patients with breast cancer: a retrospective study.<\/span>
                          \nAnticancer Res. 42(5): 2591-2598 (2022) DOI:                           10.21873\/anticanres.15737.<\/a><\/span><\/li>\n
                        5. <\/li>\n<\/ol>\n
                            \n
                          1. <\/li>\n<\/ol>\n<\/div>\n
                            <\/div>\n
                            2021\u5e74<\/span><\/div>\n
                            \n

                            \u53d7\u8cde<\/h2>\n
                              \n
                            1. \u6c60\u6751 \u5065\u6cbb\u30002021\u5e74\u5ea6\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a \u5968\u52b1\u8cde<\/span>
                              \n\u85ac\u7269\u52d5\u614b\u5b66\u7684\u30a2\u30d7\u30ed\u30fc\u30c1\u3092\u57fa\u76e4\u3068\u3057\u305f\u304c\u3093\u85ac\u7269\u7642\u6cd5\u306e\u526f\u4f5c\u7528\u56de\u907f\u306b\u5411\u3051\u305f\u30a8\u30d3\u30c7\u30f3\u30b9\u69cb\u7bc9<\/span><\/li>\n
                            2. \u539f \u4f38\u8f14\u3000\u7b2c31\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a \u512a\u79c0\u6f14\u984c\u8cde<\/span>
                              \n\u30c8\u30ea\u30d5\u30eb\u30ea\u30b8\u30f3\uff0f\u30c1\u30d4\u30e9\u30b7\u30eb\u306e\u6295\u4e0e\u30b9\u30b1\u30b8\u30e5\u30fc\u30eb\u5909\u66f4\u306b\u304a\u3051\u308b\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027\u306e\u5f8c\u2f45\u8996\u7684\u691c\u8a0e<\/span><\/li>\n<\/ol>\n
                                <\/ol>\n<\/div>\n

                                \u8ad6\u6587\u767a\u8868<\/h2>\n
                                  \n
                                1. Yokoyama H, Shioyama W, Shintani T, Maeda S, Hirobe S, Maeda M, Sakata Y, Fujio Y. <\/span>
                                  \nVascular endothelial growth factor receptor inhibitors impair left ventricular diastolic functions.<\/span>
                                  \nInt Heart J. 62(6): 1297-1304 (2021) DOI: 10.1536\/ihj.21-307.<\/a><\/span><\/li>\n
                                2. Hirobe S, Susai R, Takeuchi H, Eguchi R, Ito S, Quan Y, Kamiyama F, Okada N.<\/span>
                                  \nCharacteristics of immune induction by transcutaneous vaccination using dissolving microneedle patches in mice.<\/span>
                                  \nInt J Pharm. 601: 120563. (2021) DOI:                                   10.1016\/j.ijpharm.2021.120563.<\/a><\/span><\/li>\n
                                3. <\/li>\n
                                4. Wakai E, Ikemura K, Kato C, Okuda M. <\/span>
                                  \nEffect of number of medications and complexity of regimens on medication adherence and blood pressure management in hospitalized patients with hypertension.<\/span>
                                  \nPLoS ONE. 16(6): e0252944. (2021) DOI: <\/span><\/span><\/span>                                  <\/a>10.1371\/journal.pone.0252944.<\/a><\/span><\/li>\n
                                5. Enokiya T, Nishikawa K, Hamada Y, Ikemura K, Sugimura Y, Okuda M.<\/span>
                                  \nTemporary\u00a0decrease\u00a0in\u00a0tacrolimus clearance\u00a0in cytochrome P450 3A5 non-expressors early after living donor kidney transplantation: Effect of interleukin 6-induced suppression of the cytochrome P450 3A gene.\u00a0<\/span>
                                  \nBasic Clin Pharmacol Toxicol. 128(3): 525-533 (2021) DOI:                                   10.1111\/bcpt.13539.<\/a><\/span><\/li>\n
                                6. Okamoto A, Ikemura K, Mizutani E, Iwamoto T, Okuda M. <\/span>
                                  \nOpioid therapy duration before naldemedine treatment is a significant independent risk of diarrhea: a retrospective cohort study.<\/span>
                                  \nJ Pharm Health Care Sci. 7(1): 3 (2021) DOI:                                   10.1186\/s40780-020-00187-3.<\/a><\/span><\/li>\n
                                7. \u6751\u5730\u5eb7\u3001\u7d30\u5ddd\u7950\u5c90\u3001\u8863\u7b20\u88d5\u9999\u3001\u5c71\u672c\u667a\u4e5f\u3001\u5965\u7530\u771f\u5f18<\/span>
                                  \n\u6297\u304c\u3093\u5264\u306e\u5b9f\u5730\u8abf\u88fd\u306b\u304a\u3051\u308b\u66dd\u9732\u5bfe\u7b56\u3068\u3057\u3066\u306e\u30cd\u30aa\u30b7\u30fc\u30eb\u30c9\u00ae\u306e\u6709\u7528\u6027\u8a55\u4fa1<\/span>
                                  \n\u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u96d1\u8a8c\u300157(1): 63-69 (2021)<\/span><\/li>\n
                                8. \u4e2d\u6751\u6d0b\u5e73\u3001\u2f29\u5009\u88d5\u53f8\u3001\u677e\u4e95\u6d69\u5b50\u3001\u524d\u7530\u771f\u4e00\u90ce\u3001\u5d8b\u6d25\u5cb3\u58eb<\/span>
                                  \n\u6301\u7d9a\u8840\u6db2\u6ffe\u904e\u900f\u6790\u306b\u3088\u308a\u6539\u5584\u3057\u305f\u30e1\u30c8\u30db\u30eb\u30df\u30f3\u306b\u3088\u308b\u4e73\u9178\u30a2\u30b7\u30c9\u30fc\u30b7\u30b9\u306e1\u4f8b.<\/span>
                                  \n\u65e5\u672c\u6551\u6025\u533b\u5b66\u4f1a\u96d1\u8a8c\u300132: 86-91 (2021)<\/span><\/li>\n<\/ol>\n<\/div>\n<\/div>\n
                                  \n
                                  \n
                                  2020\u5e74<\/span><\/div>\n

                                  \u8ad6\u6587\u767a\u8868<\/h2>\n
                                    \n
                                  1. Ogami C, Tsuji Y, Muraki Y, Mizoguchi A, Okuda M, To H.<\/span>
                                    \nPopulation pharmacokinetics and pharmacodynamics of teicoplanin and C-reactive protein in hospitalized patients with gram-positive infections.<\/span>
                                    \nClin Pharmacol Drug Dev. 9: 175-188 (2020) DOI:                                     10.1002\/cpdd.684.<\/a><\/span><\/li>\n
                                  2. Enokiya T, Hasegawa M, Muraki Y, Morikawa Y, Iwamoto T, Sudo A, Okuda M. <\/span>
                                    \nPostoperative anaemia is a risk factor for major bleeding in thromboprophylaxis using fondaparinux sodium injection after total knee or hip arthroplasty. <\/span>
                                    \nBiol Pharm Bull. 43: 266-271 (2020) DOI:                                     10.1248\/bpb.b19-00447.<\/a><\/span><\/li>\n
                                  3. Urano K, Ishibashi M, Matsumoto T, Ohishi K, Muraki Y, Iwamoto T, Kunimasa J, Okuda M. <\/span>
                                    \nImpact of physician\u2212pharmacist collaborative protocol-based pharmacotherapy management for HIV outpatients: a retrospective cohort study. <\/span>
                                    \nJ Pharm Health Care Sci. 6: 9 (2020) DOI:                                     10.1186\/s40780-020-00165-9.<\/a><\/span><\/li>\n
                                  4. Hiramatsu S, Ikemura K, Fujisawa Y, Iwamoto T, Okuda M.<\/span>
                                    \nConcomitant lansoprazole ameliorates cisplatin-induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats.<\/span>
                                    \nBiopharm Drug Dispos. 41(6): 239-247 (2020) DOI:                                     10.1002\/bdd.2242.<\/a><\/span><\/li>\n
                                  5. Ichihashi K, Hori H, Hasegawa N, Yasuda Y, Yamamoto T, Tsuboi T, Iwamoto K, Kishimoto T, Horai T, Yamada H, Sugiyama N, Nakamura T, Tsujino N, Nemoto K, Oishi S, Usami M, Katsumoto E, Yamamori H, Tomita H, Suwa T, Furihata R, Inagaki T, Fujita J, Onitsuka T, Miura K, Matsumoto J, Ohi K, Matsui Y, Takaesu Y, Hashimoto N, Iga J, Ogasawara K, Yamada H, Watanabe K, Inada K, Hashimoto R. <\/span>
                                    \nPrescription patterns in patients with schizophrenia in Japan: first-quality indicator data from the survey of \u201cEffectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)\u201d project.<\/span>
                                    \nNeuropsychopharmacol Rep. 40(3): 281-286 (2020) DOI:                                     10.1002\/npr2.12122.<\/a><\/span><\/li>\n
                                  6. Iida H, Iga J, Hasegawa N, Yasuda Y, Yamamoto T, Miura K, Matsumoto J, Murata A, Ogasawara K, Yamada H, Hori H, Ichihashi K, Hashimoto N, Ohi K, Yasui-Furukori N, Tsuboi T, Nakamura T, Usami M, Furihata R, Takaesu Y, Iwamoto K, Sugiyama N, Kishimoto T, Tsujino N, Yamada H, Hishimoto A, Nemoto K, Atake K, Muraoka H, Katsumoto E, Oishi S, Inagaki T, Ito F, Imamura Y, Kido M, Nagasawa T, Numata S, Ochi S, Iwata M, Yamamori H, Fujita J, Onitsuka T, Yamamura S, Makinodan M, Fujimoto M, Takayanagi Y, Takezawa K, Komatsu H, Fukumoto K, Tamai S, Yamagata H, Kubota C, Horai T, Inada K, Watanabe K, Kawasaki H, Hashimoto R. <\/span>
                                    \nUnmet need for major depressive disorders-Findings from the \u2018Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)\u2019 project: A nationwide dissemination, education, and evaluation study.<\/span>
                                    \nPsychiatry Clin Neurosci. 74(12): 667-669 (2020) DOI:                                     10.1111\/pcn. 13143.<\/a><\/span><\/li>\n
                                  7. Wakai E, Suzumura Y, Ikemura K, Mizuno T, Watanabe M, Takeuchi K, Nishimura Y.<\/span>
                                    \nAn Integrated in silico and in vivo approach to identify protective effects of palonosetron in cisplatin-induced nephrotoxicity.<\/span>
                                    \nPharmaceuticals. 13(12): 480 (2020) DOI:                                     10.3390\/ph13120480.<\/span><\/a><\/span><\/li>\n
                                  8. Mizutani H, Shiga C, Imai M, Ikemura K, Kitamura Y, Ohta K, Miyazawa D, Sakanashi M, Tahira T, Maeda T, Hiraku Y, Kawanishi S.<\/span>
                                    \nIdarubicin, an anthracycline, induces oxidative DNA damage in the presence of copper (II).<\/span>
                                    \nAnticancer Res. 40(10): 5399-5404 (2020) DOI:                                     10.21873\/anticanres.14548.<\/a><\/span><\/li>\n
                                  9. Lin Y, Higashisaka K, Shintani T, Maki A, Hanamuro S, Haga Y, Maeda S, Tsujino H, Nagano K, Fujio Y, Tsutsumi Y.<\/span>
                                    \nProgesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt\/\u03b2-catenin and NF-\u03baB pathways, in lung adenocarcinoma cells.<\/span>
                                    \nSci Rep. 10(1): 4748 (2020) DOI:                                     10.1038\/s41598-020-61727-3<\/span>.<\/a><\/span><\/li>\n
                                  10. \u82e5\u4e95\u6075\u91cc\uff0c\u6c60\u6751\u5065\u6cbb\uff0c\u5c71\u5d0e\u5927\u8f14\uff0c\u77f3\u539f\u5e79\u4e5f\uff0c\u5ca9\u672c\u5353\u4e5f\uff0c\u5965\u7530\u771f\u5f18<\/span>
                                    \n\u9ad8\u901f\u6db2\u4f53\u30af\u30ed\u30de\u30c8\u30b0\u30e9\u30d5\u30a3\u30fc(HPLC)\u3092\u7528\u3044\u305f\u7c21\u4fbf\u306a\u8840\u6e05\u4e2d\u30df\u30c8\u30bf\u30f3\u6fc3\u5ea6\u6e2c\u5b9a\u6cd5\u306e\u958b\u767a\u3068\u81e8\u5e8a\u5fdc\u7528.<\/span>
                                    \nTDM\u7814\u7a76\u300137 (2): 77-83 (2020)<\/span><\/li>\n
                                  11. \u677e\u4e95\u6d69\u5b50\uff0c\u7af9\u5ddd\u826f\u4ecb\uff0c\u5927\u897f\u5149\u96c4\uff0c\u9580\u8107\u88d5\u5b50\uff0c\u5d8b\u6d25\u5cb3\u58eb<\/span>
                                    \n\u30a2\u30b7\u30af\u30ed\u30d3\u30eb\u8133\u75c7\u306e1\u4f8b\u2015\u814e\u6a5f\u80fd\u969c\u5bb3\u4e0b\u3067\u306e\u30a2\u30b7\u30af\u30ed\u30d3\u30eb\u6295\u4e0e\u306b\u95a2\u3059\u308b\u8003\u5bdf\u2015<\/span>
                                    \n\u4e2d\u6bd2\u7814\u7a76\u300133(3): 216-218 (2020)<\/span><\/li>\n<\/ol>\n<\/div>\n<\/div>\n
                                    \n
                                    \n
                                    2019\u5e74<\/span><\/div>\n

                                    \u53d7\u8cde<\/h2>\n
                                      \n
                                    1. \u65b0\u8c37 \u62d3\u4e5f\u3000\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1aPostdoctral Award<\/span>
                                      \n\u65b0\u898fEGFR-TKI\u8010\u6027\u7372\u5f97\u56e0\u5b50eIF3c\u306e\u5206\u5b50\u75c5\u7406\u5b66\u7684\u610f\u7fa9\u306e\u89e3\u660e\u3068\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u3068\u3057\u3066\u306e\u6709\u7528\u6027\u306e\u691c\u8a0e<\/span><\/li>\n<\/ol>\n

                                      \u8ad6\u6587\u767a\u8868<\/h2>\n
                                        \n
                                      1. Kitayama K, Maeda S, Nakamura A, Katayama I, Wataya-Kaneda M.\u00a0<\/span>
                                        \nEfficiency of sirolimus delivery to the skin is dependent on administration route and formulation.\u00a0<\/span>
                                        \nJ Dermatol Sci. 94: 350-353 (2019) DOI: 10.1016\/j.jdermsci.2019.05.002.<\/span><\/a><\/span><\/li>\n
                                      2. Nakagami H, Sugimoto K, Ishikawa T, Koshizaka M, Fujimoto T, Kiyohara E, Hayashi M, Nakagawa Y, Ando H, Terabe Y, Takami Y, Yamamoto K, Takeya Y, Takemoto M, Ebihara T, Nakamura A, Nishikawa M, Xiang Jing Yao, Hanaoka H, Yokote K, Rakugi H.\u00a0<\/span>
                                        \nInvestigator-initiated clinical study of a functional peptide, SR-0379, for limb ulcers of patients with Werner syndrome as a pilot study.\u00a0<\/span>
                                        \nGeriatr Gerontol Int. 19(11): 1118-1123 (2019) DOI:                                         10.1111\/ggi.13782.<\/span><\/a><\/span><\/li>\n
                                      3. Ju N, Shimamura M, Hayashi H, Ikeda Y, Yoshida S, Nakamura A, Morishita R, Rakugi H, Nakagami H.\u00a0<\/span>
                                        \nPreventative effects of the partial RANKL peptide MHP1-AcN in a mouse model of imiquimodinduced psoriasis.\u00a0<\/span>
                                        \nSci Rep. 9(1): 15434 (2019) DOI:                                         10.1038\/s41598-019-51681-0.<\/span><\/a><\/span><\/li>\n
                                      4. Kokado R, Hagiya H, Morii D, Okuno H, Yamamoto N, Hamaguchi S, Yoshida H, Miwa Y. Tomono K.\u00a0<\/span>
                                        \nBroad-spectrum antibiotic prescriptions are discontinued unevenly throughout the week.\u00a0<\/span>
                                        \nJ Hosp Infect. 101(4): 471-474 (2019) DOI:                                         10.1016\/j.jhin.2018.11.004.<\/span><\/a><\/span><\/li>\n
                                      5. Kokado R, Hagiya H, Koyama T, Matsui E, Okuno H, Morii D, Hamaguchi S, Yoshida H, Miwa Y, Tomono K.\u00a0<\/span>
                                        \nAntibiotic-associated adverse drug events at a Japanese academic hospital.\u00a0<\/span>
                                        \nJ Infect Chemother. 25(5): 392-395 (2019) DOI:                                         10.1016\/j.jiac.2018.11.002.<\/span><\/a><\/span><\/li>\n
                                      6. Hagiya H, Kokado R, Okuno H, Tomono K.\u00a0<\/span>
                                        \nDaptomycin-associated myopathy induced by concomitant administration of mirabegron.\u00a0<\/span>
                                        \nInfection. 47(2): 331-332 (2019) DOI:                                         10.1007\/s15010-018-1252-z.<\/span><\/a><\/span><\/li>\n
                                      7. Morii D, Kokado R, Tomono K.\u00a0<\/span>
                                        \nHospital-by-hospital carbapenem use in Japan: a nationwide ecological study.\u00a0<\/span>
                                        \nJ Hosp Infect. 102(1):101-107 (2019) DOI:                                         10.1016\/j.jhin.2018.11.009.<\/span><\/a><\/span><\/li>\n
                                      8. Hagiya H, Kokado R, Ueda A, Okuno H, Morii D, Hamaguchi S, Yamamoto N, Yoshida H, Tomono K.\u00a0<\/span>
                                        \nAssociation of Adverse Drug Events with Broad-spectrum Antibiotic Use in Hospitalized Patients: A Single-centered Study.\u00a0<\/span>
                                        \nIntern Med. 58(18): 2621-2625 (2019) DOI: 1                                        0.2169\/internalmedicine.2603-18.<\/a><\/span><\/span><\/li>\n
                                      9. Ikemura K, Hiramatsu S, Shinogi Y, Nakatani Y, Tawara I, Iwamoto T, Katayama N, Okuda M.\u00a0<\/span>
                                        \nConcomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein.\u00a0<\/span>
                                        \nSci Rep. 9(1): 20359 (2019) DOI:                                         10.1038\/s41598-019-56900-2.<\/span><\/a><\/span><\/li>\n
                                      10. Matsuura H, Ujiie K, Duyen TTM, Izutsu K, Fujiyama K, Maeda S, Harada K, Hirata K.\u00a0<\/span>
                                        \nDevelopment of a Paper-Based Luminescence Bioassay for Therapeutic Monitoring of Aminoglycosides: a Proof-of-Concept Study.\u00a0<\/span>
                                        \nApplied Biochemistry and Biotechnology. 189(3): 798-809 (2019) DOI:                                         10.1007\/s12010-019-03048-4.<\/span><\/a><\/span><\/li>\n
                                      11. Sasano M, Ohno M, Fukuda Y, Nonen S, Hirobe S, Maeda S, Miwa Y, Yokoyama J, Nakayama H, Miyagawa S, Sawa Y, Fujio Y, Maeda M.\u00a0<\/span>
                                        \nVerification of pharmacogenomics-based algorithms to predict warfarin maintenance dose using registered data of Japanese patients.\u00a0<\/span>
                                        \nEur J Clin Pharmacol. 75(7): 901-911 (2019) DOI:                                         10.1007\/s00228-019-02656-7.<\/span><\/a><\/span><\/li>\n
                                      12. \u6d66\u5d8b\u5eb8\u5b50\u3001\u5ca9\u672c\u745e\u6a39\u3001\u6c60\u7530\u8ce2\u4e8c\u3001\u7c73\u7530\u52c7\u592a\u3001\u4e95\u4e0a\u9ebb\u8863\u3001\u677e\u672c\u6570\u535a\u3001\u5c71\u5d0e\u8087\u3001\u897f\u5ddd\u6e80\u5247\u3001\u5ee3\u8c37\u82b3\u5f66\u00a0<\/span>
                                        \n\u9662\u5185\u88fd\u5264\u30d5\u30a7\u30ce\u30fc\u30eb\u30b0\u30ea\u30bb\u30ea\u30f3\u6ce8\u5c04\u5264\u306e\u5b89\u5b9a\u6027\u8a55\u4fa1\u00a0<\/span>
                                        \n\u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u96d1\u8a8c\u300155(10): 1191-1194 (2019)<\/span><\/li>\n<\/ol>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

                                        2026\u5e74 \u53d7\u8cde \u6e05\u672c \u7434\u6dd1\u3000\u65e5\u672c\u85ac\u5b66\u4f1a\u7b2c146\u5e74\u4f1a \u5b66\u751f\u512a\u79c0\u767a\u8868\u8cde\uff08\u30dd\u30b9\u30bf\u30fc\u767a\u8868\u306e\u90e8\uff09 \u5b9f\u81e8\u5e8a\u30c7\u30fc\u30bf\u3092\u7528\u3044\u305f\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u8a98\u767a\u6027\u814e\u969c\u5bb3\u306e\u6a5f\u68b0\u5b66\u7fd2\u30d9\u30fc\u30b9\u4e88\u6e2c\u30e2\u30c7\u30eb\u306e\u69cb\u7bc9 \u9577\u8c37 \u5f69\u82b1\u3000\u5927\u962a\u5927\u5b66\u85ac\u5b66\u90e8\u3000\u4ee4\u548c7\u5e74\u5ea6\u9577\u671f\u8ab2\u984c\u7814\u7a76\u4e2d […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-cat1.php","meta":[],"_links":{"self":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/hp-drug\/pharm\/wp-json\/wp\/v2\/pages\/24"}],"collection":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/hp-drug\/pharm\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/hp-drug\/pharm\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/hp-drug\/pharm\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/hp-drug\/pharm\/wp-json\/wp\/v2\/comments?post=24"}],"version-history":[{"count":135,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/hp-drug\/pharm\/wp-json\/wp\/v2\/pages\/24\/revisions"}],"predecessor-version":[{"id":2964,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/hp-drug\/pharm\/wp-json\/wp\/v2\/pages\/24\/revisions\/2964"}],"wp:attachment":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/hp-drug\/pharm\/wp-json\/wp\/v2\/media?parent=24"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}